Gene Manipulation In Human Embryos Provokes Ethical Questions
By Rahel Gebreyes,
HuffPost Live
| 11. 17. 2015
[cites CGS' Marcy Darnovsky]
Untitled Document
A team of Chinese scientists raised eyebrows in April when they modified the genetic code of human embryos to correct the gene defect that causes the hereditary blood disease beta-thalassemia. Now, many researchers and ethicists fear that the technology used to make those manipulations might one day be "exploited for non-therapeutic modifications" such as selecting for intelligence and physical appearance.
While gene editing technology may offer serious health opportunities, it also poses ethical questions, especially if scientists use it for reasons other than preventing illness or diseases, according to Dr. Marcy Darnovsky, executive director of the Center for Genetics and Society.
"Using gene editing on human embryos for reproduction -- that's not really even a medical approach. That's not treating anybody who is sick. That's creating new human beings," Darnovsky told HuffPost Live's Josh Zepps in a video segment (above) on Monday.
As she explained, gene-modification skeptics have raised a number of objections to the budding technology. Darnovsky said:
"There are totally secular objections to it -- having to do with the safety, having to do with the fact...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...